会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
    • 新型姜黄素因子VIIa构建成肿瘤生长和血管生成抑制因子
    • US20060229239A9
    • 2006-10-12
    • US10383898
    • 2003-03-07
    • Mamoru ShojiJames SnyderDennis LiottaAiming Sun
    • Mamoru ShojiJames SnyderDennis LiottaAiming Sun
    • A61K38/17
    • C12Y304/21021A61K47/64A61K47/6425C07D213/63C12N9/6437
    • The fluorinated curcuminoid (3,5-bis-(2-fluorobenzylidene)-piperidin-4-one-acetate is about ten times more effective at arresting the growth of tumor cells than cisplatin. The present invention provides methods to deliver a cytotoxic compound, such as a curcuminoid, specifically to cancer cells and to the vascular endothelial cells that nourish solid tumors. The method involves tethering the drug to a protein such as in factor VIIa that retains high affinity for the surface protein tissue factor. Upon complexation, the resulting heterodimer is endocytosed and the drug is subsequently liberated inside the target cell via proteolytic cleavage. The present invention further provides for the synthesis of novel curcuminoid-tether-linker-factor VIIa compositions and for methods of delivery of effective doses of the novel compositions to target tumor or endothelial cells in a patient
    • 氟化姜黄素(3,5-双 - (2-氟亚苄基) - 哌啶-4-酮乙酸酯在阻止肿瘤细胞生长方面比顺铂高约十倍。本发明提供递送细胞毒性化合物的方法, 例如姜黄素,特别是癌细胞和滋养实体瘤的血管内皮细胞,该方法涉及将药物系在蛋白质上,例如对表面蛋白组织因子保持高亲和力的因子VIIa,在复合后,产生 异二聚体被内吞,并且药物随后通过蛋白水解切割在靶细胞内释放。本发明还提供了新型姜黄素 - 连接子 - 连接因子VIIa组合物的合成和用于将有效剂量的新组合物递送至靶 肿瘤或内皮细胞